In this talk, we will highlight opportunities and challenges for the implementation of pathogen agnostic sequencing in the context of the wider global community, and lessons learned from the GEIS program.
Pathogen agnostic sequencing is crucial for biodefense and public health, aiding in infectious disease detection and monitoring. The GEIS program leveraged early DoD biodefense and medical research investments in pathogen sequencing to enhance infectious disease surveillance activities performed by GEIS partner laboratories around the world.
Next-generation sequencing (NGS) technologies, which offer higher-throughput genome sequencing, have become more affordable and widely adopted in biomedical and public health labs. The reduced cost per genome or sample has made NGS a key part of routine public health surveillance.
While pathogen agnostic sequencing technologies and testing approaches have matured and become more accessible, fewer considerations have been made for the operationalization of agnostic sequencing within the context of an infectious disease surveillance system.